Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Confirmation of results
Investor presentation
Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms that the Group's interim results for the six months ended 30 June will be announced on Tuesday 10 September 2024.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Tuesday 10 September 2024. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.
For more information:
| Tissue Regenix Group plc | |
| Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer | via Walbrook PR |
| | |
| Cavendish Capital Markets Limited (Nominated Adviser and Broker) | |
| Emily Watts/Geoff Nash/ Edward Whiley - Corporate Finance | |
| Nigel Birks/Harriet Ward - ECM | |
|
| |
| Walbrook PR (Financial PR and IR) | Tel: +44 (0)20 7933 8780 |
| Charlotte Edgar / Alice Woodings | TissueRegenix@walbrookpr.com |
| | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
